Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Systemic Therapy of Metastatic Melanoma: On the Road to Cure.

Tytuł :
Systemic Therapy of Metastatic Melanoma: On the Road to Cure.
Autorzy :
Steininger J; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
Gellrich FF; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
Schulz A; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
Westphal D; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
Beissert S; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
Meier F; Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
Pokaż więcej
Źródło :
Cancers [Cancers (Basel)] 2021 Mar 20; Vol. 13 (6). Date of Electronic Publication: 2021 Mar 20.
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Original Publication: Basel, Switzerland : MDPI
References :
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
Mol Cancer. 2018 Feb 19;17(1):26. (PMID: 29455657)
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. (PMID: 30959471)
J Immunother Cancer. 2019 Jun 6;7(1):145. (PMID: 31171039)
Eur J Cancer. 2017 Mar;73:85-92. (PMID: 28169047)
J Immunol. 2014 Jun 15;192(12):5451-8. (PMID: 24907378)
Cell Mol Life Sci. 2015 Apr;72(7):1249-60. (PMID: 25433395)
J Clin Oncol. 2020 Nov 20;38(33):3947-3970. (PMID: 32228358)
N Engl J Med. 2004 Sep 2;351(10):998-1012. (PMID: 15342808)
Gene Ther. 2003 Feb;10(4):292-303. (PMID: 12595888)
Clin Cancer Res. 2016 Feb 1;22(3):680-90. (PMID: 26832745)
JAMA Oncol. 2019 Feb 1;5(2):187-194. (PMID: 30422243)
J Clin Oncol. 2015 Sep 1;33(25):2780-8. (PMID: 26014293)
Science. 2002 Oct 25;298(5594):850-4. (PMID: 12242449)
Nat Med. 2012 Jun;18(6):980-7. (PMID: 22561687)
N Engl J Med. 2012 Jul 12;367(2):107-14. (PMID: 22663011)
N Engl J Med. 2019 Aug 15;381(7):626-636. (PMID: 31166680)
Lancet. 2020 Jun 13;395(10240):1835-1844. (PMID: 32534646)
Clin Cancer Res. 2014 Nov 1;20(21):5537-46. (PMID: 24803579)
Eur J Cancer. 2019 May;112:38-46. (PMID: 30909072)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Eur J Cancer. 2020 May;130:126-138. (PMID: 32179447)
Lancet Oncol. 2019 Sep;20(9):1239-1251. (PMID: 31345627)
Ann Oncol. 2020 Nov;31(11):1435-1448. (PMID: 32763453)
J Clin Med. 2020 Jan 14;9(1):. (PMID: 31947592)
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. (PMID: 29442540)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32221017)
J Invest Dermatol. 2021 Jan;141(1):23-31. (PMID: 32268150)
Acta Oncol. 2020 Apr;59(4):434-437. (PMID: 31920132)
Br J Cancer. 2016 Nov 22;115(11):1280-1284. (PMID: 27711085)
Lancet. 2015 Aug 1;386(9992):444-51. (PMID: 26037941)
N Engl J Med. 2015 Jan 22;372(4):320-30. (PMID: 25399552)
EMBO J. 1992 Nov;11(11):3887-95. (PMID: 1396582)
Trends Mol Med. 2006 Sep;12(9):406-14. (PMID: 16899407)
Br J Cancer. 1996 Sep;74(6):951-5. (PMID: 8826864)
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. (PMID: 30865922)
Lancet Oncol. 2017 Jul;18(7):863-873. (PMID: 28592387)
Cancer J. 2012 Mar-Apr;18(2):142-7. (PMID: 22453015)
N Engl J Med. 2011 Jun 30;364(26):2507-16. (PMID: 21639808)
Lancet Oncol. 2012 May;13(5):459-65. (PMID: 22456429)
Lancet Oncol. 2016 Sep;17(9):1248-60. (PMID: 27480103)
Ann Oncol. 2019 Dec 1;30(12):1884-1901. (PMID: 31566661)
Int J Oncol. 2018 Apr;52(4):1071-1080. (PMID: 29532857)
Cancer. 2011 Apr 15;117(8):1687-96. (PMID: 20960525)
N Engl J Med. 2015 Jan 1;372(1):30-9. (PMID: 25399551)
Nature. 2002 Jun 27;417(6892):949-54. (PMID: 12068308)
Clin Exp Metastasis. 2017 Oct;34(6-7):401-410. (PMID: 29063238)
Int J Cancer. 2020 Mar 15;146(6):1479-1489. (PMID: 31583684)
Head Neck. 2016 Dec;38(12):1752-1758. (PMID: 27407058)
J Clin Oncol. 2019 Apr 10;37(11):867-875. (PMID: 30811280)
J Exp Med. 1995 Aug 1;182(2):459-65. (PMID: 7543139)
Cancer. 2017 Jun 1;123(S11):2163-2175. (PMID: 28543697)
Cancers (Basel). 2019 Oct 24;11(11):. (PMID: 31653096)
N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797)
Lancet Oncol. 2017 Apr;18(4):435-445. (PMID: 28284557)
N Engl J Med. 2006 Jul 6;355(1):51-65. (PMID: 16822996)
Cancer Res. 2011 Apr 1;71(7):2750-60. (PMID: 21317224)
Sci Rep. 2020 Aug 4;10(1):13160. (PMID: 32753702)
Eur J Cancer. 2020 Feb;126:33-44. (PMID: 31901705)
Science. 1995 Nov 10;270(5238):932-3. (PMID: 7481795)
N Engl J Med. 2015 Jul 2;373(1):23-34. (PMID: 26027431)
PLoS One. 2017 Jul 5;12(7):e0179431. (PMID: 28678791)
Lancet Oncol. 2018 May;19(5):603-615. (PMID: 29573941)
J Exp Med. 1994 Mar 1;179(3):1005-9. (PMID: 8113668)
Pigment Cell Melanoma Res. 2020 May;33(3):498-506. (PMID: 31646741)
Cancer Discov. 2020 Aug;10(8):1158-1173. (PMID: 32439653)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Ann Oncol. 2018 Oct 1;29(10):2115-2120. (PMID: 30137228)
Cancer Biol Med. 2014 Dec;11(4):237-46. (PMID: 25610709)
Front Immunol. 2019 May 07;10:990. (PMID: 31134073)
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):96-100. (PMID: 26629272)
Int J Mol Sci. 2018 Dec 03;19(12):. (PMID: 30513872)
Clin Cancer Res. 2006 Nov 15;12(22):6737-47. (PMID: 17121894)
N Engl J Med. 2015 Jun 25;372(26):2521-32. (PMID: 25891173)
Ann Surg Oncol. 2016 Dec;23(13):4169-4177. (PMID: 27342831)
Lancet Oncol. 2018 May;19(5):672-681. (PMID: 29602646)
Lancet Oncol. 2018 Nov;19(11):1480-1492. (PMID: 30361170)
J Immunol. 2007 May 1;178(9):5727-34. (PMID: 17442956)
Expert Rev Anticancer Ther. 2009 May;9(5):587-95. (PMID: 19445576)
Pharmacol Res. 2018 Oct;136:151-159. (PMID: 30145328)
Science. 2015 Apr 3;348(6230):62-8. (PMID: 25838374)
Melanoma Res. 2015 Aug;25(4):362-6. (PMID: 26061438)
Ann Oncol. 2019 Apr 1;30(4):582-588. (PMID: 30715153)
J Clin Oncol. 1991 Apr;9(4):641-8. (PMID: 2066760)
N Engl J Med. 2012 Jun 28;366(26):2517-9. (PMID: 22658126)
Cancer Discov. 2019 Jun;9(6):711-721. (PMID: 30988166)
N Engl J Med. 2014 Nov 13;371(20):1867-76. (PMID: 25265494)
Am J Clin Dermatol. 2017 Feb;18(1):1-15. (PMID: 27988837)
Ann Oncol. 2019 Jul 1;30(7):1154-1161. (PMID: 30923820)
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. (PMID: 28881921)
Nat Rev Dis Primers. 2015 Apr 23;1:15003. (PMID: 27188223)
Contributed Indexing :
Keywords: BRAF inhibitors; Immune checkpoint inhibitors; MEK inhibitors; melanoma; systemic therapy
Entry Date(s) :
Date Created: 20210403 Latest Revision: 20210408
Update Code :
20210914
PubMed Central ID :
PMC8003858
DOI :
10.3390/cancers13061430
PMID :
33804800
Czasopismo naukowe
This decade has brought significant survival improvement in patients with metastatic melanoma with targeted therapies and immunotherapies. As our understanding of the mechanisms of action of these therapeutics evolves, even more impressive therapeutic success is being achieved through various combination strategies, including combinations of different immunotherapies as well as with other modalities. This review summarizes prospectively and retrospectively generated clinical evidence on modern melanoma therapy, focusing on immunotherapy and targeted therapy with BRAF kinase inhibitors and MEK kinase inhibitors (BRAF/MEK inhibitors), including recent data presented at major conference meetings. The combination of the anti-PD-1 directed monoclonal antibody nivolumab and of the CTLA-4 antagonist ipilimumab achieves unprecedented 5-year overall survival (OS) rates above 50%; however, toxicity is high. For PD-1 monotherapy (nivolumab or pembrolizumab), toxicities are in general well manageable. Today, novel combinations of such immune checkpoint inhibitors (ICIs) are under investigation, for example with cytokines and oncolytic viruses (i.e., pegylated interleukin-2, talimogene laherparepvec). Furthermore, current studies investigate the combined or sequential use of ICIs plus BRAF/MEK inhibitors. Several studies focus particularly on poor prognosis patients, as e.g., on anti-PD-1 refractory melanoma, patients with brain metastases, or uveal melanoma. It is hoped, on the road to cure, that these new approaches further improve long term survival in patients with advanced or metastatic melanoma.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies